• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Brenner Louis Md sold $32,666 worth of shares (40,328 units at $0.81) and converted options into 125,582 shares (tax withholding)

    11/17/21 5:00:29 PM ET
    $ALNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    BRENNER LOUIS MD

    (Last) (First) (Middle)
    C/O ALLENA PHARMACEUTICALS, INC.
    ONE NEWTON EXECUTIVE PARK, SUITE 202

    (Street)
    NEWTON MA 02462

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Allena Pharmaceuticals, Inc. [ ALNA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    11/15/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/15/2021 S(1) 40,328 D $0.81 288,576 D
    Common Stock 11/15/2021 M 125,582 A (2) 328,904 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (2) 11/15/2021 M 125,582 (3) (3) Common Stock 125,582 $0.00 0 D
    Explanation of Responses:
    1. The sale reported on this Form 4 was effected by the Reporting Person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
    2. Each restricted stock unit represents a contingent right to receive one share of common stock.
    3. 40% shall vest on May 10, 2021 and the remaining 60% shall vest on November 10, 2021, subject to the Reporting Person's continued service through each vesting date.
    Remarks:
    /s/ Kevin Brennan, attorney-in-fact 11/17/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ALNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALNA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALNA
    Financials

    Live finance-specific insights

    See more
    • Allena Pharmaceuticals Provides Clinical and Corporate Update

      ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety profile in first cohort of patients with hyperuricemia and chronic kidney disease in the Phase 2a Study 201 Allena to host webinar to discuss the initial Study 201 data with Key Opinion Leaders Robert Terkeltaub, M.D. and David S. Goldfarb, M.D. today at 8:00 am ET; log-in information belowALLN-346 Phase 2a Study 202 is actively enrolling patients with gout and stages 2 and 3 chronic kidney disease in parallel cohorts; data from both cohorts expected in Q1 2022Company currently evaluating potenti

      1/4/22 5:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million

      NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to satisfact

      12/1/20 9:47:45 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering

      NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to sa

      12/1/20 5:00:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      2/14/23 4:09:01 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      2/14/22 4:34:57 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      1/28/22 1:42:29 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    SEC Filings

    See more
    • SEC Form SEC STAFF ACTION filed by Allena Pharmaceuticals Inc.

      SEC STAFF ACTION - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      6/12/23 2:00:02 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Allena Pharmaceuticals Inc.

      NT 10-Q - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      11/14/22 4:03:10 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Allena Pharmaceuticals Inc.

      25-NSE - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      9/14/22 9:52:49 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ALNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 4 filed by Katz Richard D

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      2/2/22 4:15:22 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Brenner Louis Md

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      2/2/22 4:15:11 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Brenner Louis Md sold $32,666 worth of shares (40,328 units at $0.81) and converted options into 125,582 shares (tax withholding)

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      11/17/21 5:00:29 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease

      NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to treat metabolic diseases, today reported completion of enrollment of the first two cohorts of its ALLN-346 Phase 2a Study 202 in gout patients with stage 2 (cohort A) and stage 3 (cohort B) chronic kidney disease (CKD). ALLN-346, which has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), is a first-in-class, non-absorbed, orally administered enzyme in development for the tr

      7/19/22 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The Special Meeting will now be held on August 4, 2022, at 9:00 a.m., local time via live webcast. The new record date for the

      7/12/22 4:05:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting, which was scheduled for July 5, 2022, to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The date of the rescheduled special meeting, and the new record date for determining the

      7/5/22 7:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The Special Meeting will now be held on August 4, 2022, at 9:00 a.m., local time via live webcast. The new record date for the

      7/12/22 4:05:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO

      - Versantis establishes wholly-owned U.S. subsidiary, Versantis, Inc. - - Current CEO, Vincent Forster, to maintain his key role as Chief Scientific Officer - Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, today announced the appointment of Mark J. Fitzpatrick as Chief Executive Officer (CEO) and member of the board of directors, effective January 1, 2022. He joins Versantis with more than 25 years of experience in the biopharma industry, primarily in senior executive roles, and will be based in the U.S. following the establishment of Versantis, Inc. He succeeds co-founder Dr. Vincent Forster, who will assume the role

      12/20/21 1:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors Allena Pharmaceuticals, Inc.

      NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors. “Mark is an experienced industry executive, who has led financial strategy at biopharmaceutical companies across all stages of development,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “His extensive experience working with late-stage, rare disease companies will be particular

      4/7/21 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care